# To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

> clinical trial · VERIFIED · 2026-07-10

Status: RECRUITING · Sponsor: Hangzhou Sumgen Biotech Co., Ltd. · Condition: Relapsed/Refractory Multiple Myeloma

- Company: Hangzhou Sumgen Biotech Co., Ltd.
- Sector: Relapsed/Refractory Multiple Myeloma
- Primary source: https://clinicaltrials.gov/study/NCT07454187

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.